This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fischli, W. Articles by Wostl, W. Search for Related Content PubMed PubMed Citation Articles by Fischli, W. Articles by Wostl, W.

Hypertension, Vol 24, 163-169, Copyright © 1994 by American Heart Association

ARTICLES

Ciprokiren (Ro 44-9375). A renin inhibitor with increasing effects on chronic treatment

W Fischli, JP Clozel, V Breu, S Buchmann, S Mathews, H Stadler, E Vieira and W Wostl
Pharma Division, Preclinical Research, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

The present study characterizes the new transition-state renin inhibitor ciprokiren (Ro 44-9375) in squirrel monkeys. Arterial blood pressure was monitored by telemetry in freely moving, chronically instrumented conscious animals. In vitro at pH 7.4, ciprokiren inhibited human renin in buffer and human plasma with an IC50 of 0.07 and 0.65 nmol/L, respectively. It was equipotent against primate plasma renin and also inhibited plasma renin from dog and guinea pig in the nanomolar range (IC50, 29 and 65 nmol/L, respectively). After acute oral administration it reduced arterial blood pressure dose dependently in normotensive sodium-depleted and cyclosporin-induced hypertensive squirrel monkeys, starting with the minimal oral dose of 3 micrograms/kg. Daily oral doses of 1 microgram/kg showed a progressive blood pressure decrease, with a maximal response reached after 1 week. The drug could also be applied transdermally with similar hemodynamic effects without any decrease of plasma renin activity or plasma immunoreactive angiotensin II. Thus, ciprokiren is characterized in squirrel monkeys as a renin inhibitor with high in vivo potency that might act mainly in the tissular compartment.

This article has been cited by other articles:

				D. R. Allan, K. Y. Hui, C. Coletti, and N. K. Hollenberg Renin vs. Angiotensin-Converting Enzyme Inhibition in the Rat: Consequences for Plasma and Renal Tissue Angiotensin J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 661 - 665. [Abstract] [Full Text]

				E. G. McMahon, P.-C. Yang, M. A. Babler, S. E. Bittner, O. D. Suleymanov, K. J. Cain-Janicki, L. J. Bedell, G. J. Hanson, and C. S. Cook Effects of SC-56525, a Potent, Orally Active Renin Inhibitor, in Salt-Depleted and Renal Hypertensive Dogs Hypertension, July 1, 1995; 26(1): 95 - 100. [Abstract] [Full Text]